Results 41 to 50 of about 3,627,015 (399)

Kinase Inhibitors as Underexplored Antiviral Agents

Journal of Medicinal Chemistry, 2021
Viral infections are a major health problem; therefore, there is an urgent need for novel therapeutic strategies. Antivirals used to target proteins encoded by the viral genome usually enhance drug resistance generated by the virus.
Javier García-Cárceles, E. Caballero, C. Gil, Ana Martínez   +3 more
semanticscholar   +1 more source

Antiviral Agents

Medical Clinics of North America, 1988
Potent effective antiviral drugs recently have been licensed for several viral diseases, ushering in a new era in the treatment of viral diseases. Several unique features in the process of a viral infection have been identified as target points for inhibition. The unique steps and the interfering compounds are the subject of this review.
Reines, Eric D., Gross, Peter A.
openaire   +2 more sources

Lycorine Derivative LY-55 Inhibits EV71 and CVA16 Replication Through Downregulating Autophagy

Frontiers in Cellular and Infection Microbiology, 2019
Hand, foot, and mouth disease (HFMD) is a global health concern, especially in the Asia-Pacific region. HFMD caused by Enterovirus 71 (EV71) and Coxsackievirus A16 (CVA16) infection is usually self-limited but occasionally leads to severe pulmonary edema,
Huiqiang Wang, Huiqiang Wang, Tingting Guo, Yajun Yang, Lian Yu, Xiandao Pan, Yuhuan Li, Yuhuan Li   +7 more
doaj   +1 more source

Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model

mBio, 2022
Amino acid substitutions I38T and E23K in the influenza polymerase acidic (PA) protein lead to reduced susceptibility to the influenza antiviral drug baloxavir.
Paulina Koszalka, Ankita George, Vijaykrishna Dhanasekaran, Aeron C. Hurt, Kanta Subbarao   +4 more
doaj   +1 more source

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals [PDF]

, 2017
In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because ...
Caputo, Mariela, Corach, Daniel, Flichman, Diego Martin, Hulaniuk, María L., Trinks, Julieta   +4 more
core   +1 more source

Direct oral anticoagulant plasma levels’ striking increase in severe COVID‐19 respiratory syndrome patients treated with antiviral agents: The Cremona experience

Journal of Thrombosis and Haemostasis, 2020
Antiviral drugs are administered in patients with severe COVID‐19 respiratory syndrome, including those treated with direct oral anticoagulants (DOACs).
S. Testa, P. Prandoni, O. Paoletti, R. Morandini, M. Tala, C. Dellanoce, M. Giorgi-Pierfranceschi, M. Betti, G. Danzi, A. Pan, G. Palareti   +10 more
semanticscholar   +1 more source

Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era

ACS Nano, 2021
Therapeutic options for the highly pathogenic human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the current pandemic coronavirus disease (COVID-19) are urgently needed.
Ã. Serrano-Aroca, K. Takayama, Alberto Tuñón-Molina, M. Seyran, S. S. Hassan, Pabitra Pal Choudhury, V. Uversky, K. Lundstrom, P. Adadi, G. Palù, Alaa A. A. Aljabali, Gaurav Chauhan, R. Kandimalla, M. Tambuwala, A. Lal, T. A. Abd El-Aziz, S. Sherchan, D. Barh, E. Redwan, N. Bazan, Y. Mishra, B. Uhal, A. Brufsky   +22 more
semanticscholar   +1 more source

Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals. [PDF]

, 2007
BackgroundThe SCID-hu Thy/Liv mouse model of HIV-1 infection is a useful platform for the preclinical evaluation of antiviral efficacy in vivo.
A Adachi, A Valentin, April N. Kinkade, Barbara Sloan, BD Jamieson, BD Jamieson, BK Berges, BS Robinson, CA Stoddart, CA Stoddart, CA Stoddart, Cheryl A. Bales, Cheryl A. Stoddart, E De Clercq, ED Miller, EJ Freireich, ES Withers-Ward, G Kovalev, George Chkhenkeli, GM Aldrovandi, GM Aldrovandi, GM Aldrovandi, H Kaneshima, H Kaneshima, J McCune, J Mordenti, Jennifer C. Bare, JF Krowka, JM McCune, JM McCune, JM McCune, JM McCune, JM Strizki, José M. Rivera, JY Feng, L Rabin, L Su, L Su, L Zhang, Linqi Zhang, LT Rimsky, M Markowitz, Mary E. Moreno, ME Keir, MG Manz, ML Bonyhadi, ML Greenberg, Paul L. Black, PS Koka, R Datema, R Namikawa, R Namikawa, RC Bast, RD Berkowitz, RD Berkowitz, RD Berkowitz, RD Berkowitz, RG Amado, Rollie E. Ronquillo, S Baenziger, S Gartner, S Gorantla, SD Young, SG Kitchen, SG Kitchen, SK Stanley, Sofiya A. Galkina, Z Sun   +67 more
core   +6 more sources

Simultaneous Antibiofilm and Antiviral Activities of an Engineered Antimicrobial Peptide during Virus-Bacterium Coinfection

mSphere, 2016
Antimicrobial-resistant infections are an urgent public health threat, and development of novel antimicrobial therapies has been painstakingly slow. Polymicrobial infections are increasingly recognized as a significant source of severe disease and also ...
Jeffrey A. Melvin, Lauren P. Lashua, Megan R. Kiedrowski, Guanyi Yang, Berthony Deslouches, Ronald C. Montelaro, Jennifer M. Bomberger   +6 more
doaj   +1 more source

Can biopolymers act as antiviral agents?

eXPRESS Polymer Letters, 2020
editorial
J. Seppala, S. Borandeh
doaj   +1 more source